Experimental
CagriSema (Cagrilintide + Semaglutide)
The prediction game
Call it: rising or fading?
Where does CagriSema (Cagrilintide + Semaglutide) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.1/10
CagriSema lands at Neutral because it pairs the strongest weight effect in this incretin batch with the weakest set of supporting facts around it. The potency is real: about 22.7% loss on-treatment, a novel amylin plus GLP-1 mechanism, and two solid Phase 3 trials, per Garvey 2025. But it is not approved anywhere, it lost a head-to-head to tirzepatide, it carries the heaviest gastrointestinal load of the batch, and there is no heart-outcomes data. For anyone needing treatment today, the approved and slightly stronger option already exists. CagriSema is worth watching closely, not chasing through gray-market channels. ✅ Best for: People researching the obesity-drug pipeline who want to understand the strongest dual-mechanism injectable on the horizon. Those who specifically want the amylin plus GLP-1 route rather than the GIP-based path, perhaps after a poor response to GIP-based drugs, though that benefit is unproven. Patients with type 2 diabetes interested in a drug that drove 74% to an HbA1c at or below 6.5% in trials, per Kahn 2025. People willing to wait for the expected FDA approval in late 2026 rather than source an unapproved drug. Anyone who can tolerate a slow 16-week ramp and a high early gastrointestinal load. ❌ Avoid if: You have a personal or family history of medullary thyroid carcinoma or MEN 2, since the class carries a thyroid C-cell warning, per Kahn 2025. You have had pancreatitis, active gallbladder disease, or severe gastrointestinal disease. You are pregnant or breastfeeding, with no safety data. You take insulin or sulfonylureas without medical supervision, since hypoglycemia risk rises. You need a treatment now, since CagriSema is not legally available and an approved, slightly stronger option exists. You cannot verify source quality, because every current channel is gray-market with real identity and purity risks.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 0.1%
- BioHarmony Score
- 5.1/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.